GlassScriptPhysician profile
James Wesley Denham
NPI 1902088644
$4,033.01
in general payments reported to CMS, 2019-2025
23 companies · $194 in 2025
The $194 reported for 2025 was more than what 79% of Anatomic Pathology & Clinical Pathology providers received nationally (typical 2025 total: $50.59).
See the full distribution for Anatomic Pathology & Clinical Pathology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $504 · 2020: $519 · 2021: $989 · 2022: $1,061 · 2023: $440 · 2024: $326 · 2025: $194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $960.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $960.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,269.42 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $501.68 | 2020-2024 | Entyvio |
| Abbvie INC. | $398.68 | 2020-2023 | Rinvoq, Skyrizi, Humira |
| Qol Medical, LLC | $181.67 | 2021-2023 | Sucraid |
| Nestle Healthcare Nutrition INC. | $122.53 | 2021-2023 | |
| Genzyme Corporation | $102.06 | 2022-2025 | |
| Daiichi Sankyo INC. | $76.15 | 2020-2022 | |
| Janssen Biotech, INC. | $44.91 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $35.51 | 2022-2024 | Dificid |
| Regeneron Healthcare Solutions, INC. | $34.93 | 2023-2025 | Dupixent |
| Enterra Medical, INC. | $32.51 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $32.44 | 2024-2025 | Iqirvo |
| Alnylam Pharmaceuticals INC. | $29.23 | 2024 | Givlaari |
| Madrigal Pharmaceuticals | $28.79 | 2025 | Rezdiffra |
| Intercept Pharmaceuticals, INC. | $25.50 | 2020-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $22.47 | 2025 | Vegzelma |
| Lilly USA, LLC | $18.98 | 2024 | Omvoh |
| Ardelyx, INC. | $14.67 | 2023 | Ibsrela |
| Aimmune Therapeutics, INC. | $14.55 | 2024 | |
| Pfizer INC. | $12.64 | 2020 | |
| Braintree Laboratories, INC. | $12.21 | 2020 | |
| Evoke Pharma, INC. | $12.09 | 2022 | |
| Mauna Kea Technologies, INC. | $9.39 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Denham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.